Login / Signup

Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control.

Marwa MohsenAhmed A ElberryAlaa Mohamed RabeaMohamed E A AbdelrahimRaghda R S Hussein
Published in: International journal of clinical practice (2020)
DPP-4 inhibitors, saxagliptin, and vildagliptin, resulted in substantial reductions in albuminuria in patients with T2D and hypertension on top of RAAS blockade after short term therapy independently on glycaemic or hemodynamic changes. Saxagliptin was superior to vildagliptin in albuminuria-categorical shifting.
Keyphrases
  • blood pressure
  • type diabetes
  • stem cells
  • bone marrow
  • cell therapy